|Day Low/High||85.47 / 90.66|
|52 Wk Low/High||17.33 / 111.36|
Could Pfizer really buy Bristol-Myers Squibb? Despite the latter's $112 billion market cap, Citi analyst Andrew Baum lays out the case for why it makes sense.
Stocks finished higher on Wednesday.
Bristol-Myers will pay $1.85 billion up front plus up to $1.78 billion in potential milestone payments to Nektar, which was reported earlier this month to be mulling options including a sale.
Bristol-Myers Squibb Company (NYSE:BMY) and Nektar Therapeutics (Nasdaq:NKTR) announced today the companies have executed a global strategic development and commercialization collaboration for Nektar's lead...
We see a notable shift away from traditional large-cap pharmaceutical stocks to more specialized niches.
It is premature to think that this market has hit a top until there is further evidence in the price action.
Interim data from the dose-escalation phase of the PIVOT-02 trial highlighted as an oral presentation
The New York-based firm reported net income of $5.25 per share, compared with a net loss of $1.71 per share, in the same period a year ago.
Company to host Investor & Analyst Event on Saturday, November 11th following an oral presentation of data from PIVOT Phase 1/2 study of NKTR-214 with nivolumab
IntelliPharmaceuticals has a bio-equivalent to OxyContin, but says it is harder to tamper with. The pharma company is hoping to gain a recommendation from an FDA committee on Wednesday.
NeuroDerm, Novavax and Nektar Therapeutics were among the biotech stock movers in premarket trading on July 24.
Puma Biotechnology, Nektar Therapeutics and Paratek Pharmaceuticals were among the biotech movers in premarket trading on July 18.
NKTR-181 is the first full mu-opioid agonist molecule designed to provide potent pain relief without the high levels of euphoria that can lead to abuse and addiction with standard opioids.
Huge profits could be on the doorstep for these hot breakout setups.
The Oracle of Omaha believes in the future of U.S. business, says Jim Cramer. Plus, Buffett can admit his mistakes and we can learn from that.
Investors in Nektar Therapeutics saw new options become available this week, for the June 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NKTR options chain for the new June 16th contracts and identified one put and one call contract of particular interest.
Jim Cramer is bullish on Nektar Therapeutics and Alkermes, as well as Verizon and Bank of America.
Jim Cramer says what's more noteworthy than the pullback is the day's strong rebound.
But what will be most important is whether support stays strong and the buyers show interest in the afternoon.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.